Why is Basilea Pharmaceutica stock surging today?

Basilea Pharmaceutica stock surged nearly 8.9% today after the Swiss biopharmaceutical company issued a sweeping upward revision to its full-year 2026 financial guidance, lifting its operating profit target to CHF 115 million from CHF 70 million previously — an increase of approximately 123% — fueled by revenues from its two marketed hospital anti-infective products, Cresemba and Zevtera, coming in well ahead of expectations.

Total revenue for the year is now projected at CHF 310 million, representing roughly a third more than the CHF 232.4 million recorded in 2025.

A key driver behind the upgrade was a sharp jump in expected milestone income, which the company now anticipates will reach CHF 65 million compared to CHF 35 million under prior guidance.

Basilea also raised the cumulative cash flow target for its "Agenda 2030" strategic initiative to CHF 650 million from CHF 600 million, and provided constructive updates on its late-stage pipeline, including a streamlined combined Phase 2/3 development pathway for ceftibuten-ledaborbactam agreed with the FDA and EMA, and continued progress in fosmanogepix Phase 3 studies.

CEO David Veitch stated: "The sustained momentum of our commercial business reinforces the financial foundations of our ’Agenda 2030’ and enhances our capacity to continue to invest in future growth." A Capital Markets Day scheduled for tomorrow in Zurich added further near-term investor focus.

The broader Swiss market has provided a supportive backdrop, with the SMI having gained meaningfully through October and outpacing European peers by a wide margin.

No specific central bank action or macro data release on today’s date appears to have independently influenced the move, making the guidance upgrade the clear and dominant driver.

Taken together, a dramatic earnings guidance raise, an elevated long-term cash flow target, positive pipeline newsflow, and a constructive Swiss equity environment combined to push Basilea shares to a new 52-week high of CHF 75.8 intraday — a move that reflects both the scale of the earnings surprise and growing investor confidence in the company’s "Agenda 2030" commercial roadmap.